UBS Group’s ENDRA Life Sciences NDRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $707 | Buy |
152
+140
| +1,167% | +$555 | ﹤0.01% | 9780 |
|
|
2025
Q4 | $54 | Sell |
12
-94
| -89% | -$536 | ﹤0.01% | 10262 |
|
|
2025
Q3 | $570 | Sell |
106
-4,589
| -98% | -$24K | ﹤0.01% | 9620 |
|
|
2025
Q2 | $16.5K | Buy |
+4,695
| New | +$18.1K | ﹤0.01% | 8567 |
|
|
2025
Q1 | – | Sell |
-95
| Closed | -$595 | – | 10555 |
|
|
2024
Q4 | $595 | Buy |
+95
| New | +$633 | ﹤0.01% | 9416 |
|
|
2024
Q3 | – | Sell |
-32
| Closed | -$5.38K | – | 9878 |
|
|
2024
Q2 | $5.38K | Buy |
+32
| New | +$13.8K | ﹤0.01% | 8003 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 8867 |
|
|
2023
Q1 | – | Sell |
-1
| Closed | -$8.75K | – | 10092 |
|
|
2022
Q4 | $8.75K | Buy |
+1
| New | +$8.38K | ﹤0.01% | 8734 |
|
|
2022
Q3 | – | Sell |
-1
| Closed | -$9K | – | 10718 |
|
|
2022
Q2 | $9K | Hold |
1
| – | – | ﹤0.01% | 8155 |
|
|
2022
Q1 | $11K | Hold |
1
| – | – | ﹤0.01% | 8306 |
|
|
2021
Q4 | $19K | Hold |
1
| – | – | ﹤0.01% | 7907 |
|
|
2021
Q3 | $49K | Hold |
1
| – | – | ﹤0.01% | 6351 |
|
|
2021
Q2 | $64K | Hold |
1
| – | – | ﹤0.01% | 6213 |
|
|
2021
Q1 | $79K | Buy |
+1
| New | +$74.9K | ﹤0.01% | 6140 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 7837 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 7128 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 7780 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 7621 |
|
|
2019
Q2 | – | Hold |
0
| – | -$3K | – | 8052 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7341 |
|
|
2018
Q2 | – | Hold |
0
| – | -$6K | – | 8159 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 7153 |
|
|
2017
Q4 | – | Hold |
0
| – | -$12K | – | 8002 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6787 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6917 |
|
Other funds holding NDRA
ACM
VFT
VCM
CIAM
UBS Group's NDRA Position: Q1 2026 in Review
UBS Group increased its ENDRA Life Sciences (NDRA) stake by 1,167% in Q1 2026, buying an estimated $555 and bringing the position to 152 shares worth $707. The position accounts for ﹤0.01% of the portfolio, ranked #9780.
UBS Group first reported a position in NDRA in Q1 2021 and has held it in 13 quarters since. The position peaked at $79K in Q1 2021. 8 funds tracked by Wall St. Rank hold NDRA as of Q1 2026.
- UBS Group held 152 shares of ENDRA Life Sciences worth $707 as of Q1 2026.
- UBS Group bought 140 ENDRA Life Sciences shares in Q1 2026, an estimated $555.
- ENDRA Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9780 holding.
- UBS Group first reported a position in ENDRA Life Sciences in Q1 2021 and has held it in 13 quarters since.
- UBS Group's ENDRA Life Sciences position peaked at $79K in Q1 2021.
- 8 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.